Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Cancer therapies

Financiado

Cerrado

Use of adoptive T cell transfer in combination with oncolytic adenoviruses for c...

Use of adoptive T cell transfer in combination with oncolytic adenoviruses for cancer treatment Metastatic cancer remains an incurable disease in the majority of cases and thus development of novel treatment strategies is required. Adoptive T cell therapy is a promising therapy for patients with a wide range of cancers. This... ver más

31/08/2015

INSTITUT CATALA D'...

224K€

Presupuesto del proyecto: 224K€

Líder del proyecto

INSTITUT CATALA D'ONCOLOGIA Actividades hospitalarias organismos publicos

TRL 4-5 | 260K€

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-08-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

INSTITUT CATALA D'ONCOLOGIA

0.00€ | Lider

FUNDACIO INSTITUT D?INVESTIG...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PolyAntiTumor Polyclonal anti-tumor immunity by engineered human T cells 2M€ Cerrado

Exh-Res-CART Exhaustion resistant CAR T cells for the treatment of solid... 161K€ Cerrado

ARMOR-T Armoring multifunctional T cells for cancer therapy 2M€ Cerrado

PID2020-119692RB-C21 ADENOVIRUS ONCOLITICOS QUE EXPRESAN PROTEINAS FORMADORAS DE... 266K€ Cerrado

T-OP Training Network for Optimizing Adoptive T cell Therapy of C... 4M€ Cerrado

INCITE Immune Niches for Cancer ImmunoTherapy Enhancement 4M€ Cerrado

Líder del proyecto

INSTITUT CATALA D'ONCOLOGIA Actividades hospitalarias organismos publicos

TRL 4-5 | 260K€

Presupuesto del proyecto 224K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Metastatic cancer remains an incurable disease in the majority of cases and thus development of novel treatment strategies is required. Adoptive T cell therapy is a promising therapy for patients with a wide range of cancers. This therapy involves ex vivo activation and expansion of T cells followed by infusion into patients. Peripheral blood CD4+ and CD8+ T cells can be redirected against tumor-associated antigens (TAA) by genetically modifying them with chimeric antigen receptors (CARs). Commonly, CARs consist of an antibody-based external receptor structure coupled to an intracellular signaling domain. Recent clinical studies using CAR-modified cells have established the feasibility and safety of this strategy in human patients. However, several hurdles have still to be overcome for a successful tumor treatment with this therapy. First, infused CAR-modified cells have short persistence in the host, limiting antitumor responses. And second, tumor creates a strong immunosuppressive environment that can impair the efficacy of infused T cells. Our hypothesis in the proposed program is that persistence and efficacy of genetically modified T cells in cancer patients can be increased by: (1) choosing the right T cell subset candidate (2) improving the signaling endodomain of CARs, (3) breaking tumor immunotolerance. In this regard, we propose that oncolytic adenoviruses, whose replication has been restricted to malignant cells, can be used to enhance tumor immunotherapy as they offer (a) tumor debulking and (b) danger signals that elicit strong immune responses. In order to test these hypothesis, the proposed program aims to (1) evaluate the contribution of different costimulatory signalling domains to CAR T cell function, (2) compare the in vivo engraftment, trafficking, persistence and efficacy of different subsets of engineered CD4+ and CD8+ T cells, including Th1, Th2, Th17 and Tc17 cells in tumor bearing mice, (3) Evaluate the ability of oncolytic adenoviruses e

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores